131 results
Page 3 of 7
8-K
EX-99.1
gl3o7 s0hi
5 Apr 21
Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives
4:13pm
S-3ASR
37z890
26 Feb 21
Automatic shelf registration
12:00am
S-3ASR
sihggdzkz qrxodi
26 Feb 21
Automatic shelf registration
12:00am
8-K
EX-99.1
bgo7f9qogmy
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm
8-K
EX-99.1
i3yzp4bln6bjlj0s5o6
26 Jan 21
Invitae Announces Pricing of Public Offering of Common Stock
4:12pm
8-K
EX-99.2
36sg8jwbnwa2
26 Jan 21
Invitae Announces Pricing of Public Offering of Common Stock
4:12pm
424B5
fctbh07vhm74y8w8
25 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
sqocfnm2 cixtd4u2
20 Jan 21
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.1
lg5 49pj0a
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.2
kj7f5
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.1
dnlpg3 ih
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K
EX-99.2
c0pcze3
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
424B7
gy7wx5ma 842kh4u
5 Nov 20
Prospectus with selling stockholder info
5:27pm
8-K
EX-99.1
no1puuqfhpq4tiaug5
5 Nov 20
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
4:24pm
8-K
EX-99.1
fkccaplgw0o
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
424B3
cdhgbrd4gp9td21n6a
28 Aug 20
Prospectus supplement
4:31pm